Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7534.084 | 0.7249 | 0.3935 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7534.084 | 0.5223 | -0.0357 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7534.084 | 0.7430 | 0.4326 | 0.8905 | |
| SUM225CWN | HER2amp | Basal A | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7534.084 | 0.1036 | -0.8432 | 0.8905 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7537.084 | 1.0041 | 1.0044 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7537.084 | 0.9650 | 0.9622 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7537.084 | 1.1168 | 1.1218 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7537.084 | 1.2217 | 1.2263 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7537.084 | 1.1793 | 1.1846 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7537.084 | 0.9107 | 0.9023 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7537.084 | 0.4247 | 0.2647 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7537.084 | 0.9963 | 0.9960 | 1.8684 | |
| SUM229PE | TNBC | - | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7537.084 | 0.7581 | 0.7245 | 1.8684 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7541.084 | 0.9845 | 0.9743 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7541.084 | 0.9628 | 0.9383 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7541.084 | 1.0405 | 1.0667 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.32 | uM | 7541.084 | 0.9491 | 0.9154 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1.6 | uM | 7541.084 | 0.6103 | 0.3295 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 8 | uM | 7541.084 | 0.5344 | 0.1913 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 40 | uM | 7541.084 | 0.3445 | -0.1715 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 200 | uM | 7541.084 | 0.3771 | -0.1072 | 1.2092 | |
| SUM52PE | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 1000 | uM | 7541.084 | 0.1245 | -0.6430 | 1.2092 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.00256 | uM | 7543.084 | 1.0331 | 1.0491 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.0128 | uM | 7543.084 | 1.0801 | 1.1181 | 1.3431 | |
| T47D | HR+ | Luminal | Sorafenib | PDGFR/VEGFR/KIT/FLT3 | RTK | 0.064 | uM | 7543.084 | 0.9514 | 0.9272 | 1.3431 |